1. Statin use and long-term risk of recurrent intracerebral haemorrhage: the MUCH-Italy.
- Author
-
Pezzini A, Tarantino B, Zedde ML, Marcheselli S, Silvestrelli G, Ciccone A, Delodovici ML, Princiotta Cariddi L, Vidale S, Paciaroni M, Azzini C, Padroni M, Gamba M, Magoni M, Del Sette M, Tassi R, de Franco IG, Cavallini A, Calabrò RS, Cappellari M, Giorli E, Giacalone G, Lodigiani C, Zenorini M, Valletta F, Pascarella R, Abrignani G, Castellini P, Genovese A, Latte L, Trapasso MC, Grisendi I, Assenza F, Napoli M, Moratti C, Beccattini S, Acampa M, Valzania F, Grassi M, and Gentilini D
- Subjects
- Humans, Male, Female, Aged, Italy epidemiology, Middle Aged, Aged, 80 and over, Risk Factors, Follow-Up Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Cerebral Hemorrhage chemically induced, Recurrence
- Abstract
Background: Whether statin use after spontaneous intracerebral haemorrhage (ICH) increases the risk of recurrent ICH is uncertain., Methods: In the setting of the Multicentric Study on Cerebral Haemorrhage in Italy we followed up a cohort of 30-day ICH survivors, consecutively admitted from January 2002 to July 2014, to assess whether the use of statins after the acute event is associated with recurrent cerebral bleeding., Results: 1623 patients (mean age, 73.9±10.3 years; males, 55.9%) qualified for the analysis. After a median follow-up of 40.5 months (25th to 75th percentile, 67.7) statin use was not associated with increased risk of recurrent ICH either in the whole study group (adjusted HR, 0.99; 95% CI 0.64 to 1.53) or in the subgroups defined by haematoma location (deep ICH, adjusted HR, 0.74; 95% CI 0.35 to 1.57; lobar ICH, adjusted HR, 1.09; 95% CI 0.62 to 1.90), intensity of statins (low-moderate intensity statins, adjusted HR, 0.93; 95% CI 0.58 to 1.49; high-intensity statins, adjusted HR, 1.48; 95% CI 0.66 to 3.31) and use of statins before the index event (adjusted HR, 0.66; 95% CI 0.38 to 1.17)., Conclusions: Statin use appears to be unrelated to the risk of ICH recurrence., Competing Interests: Competing interests: AC reports grants from Daiichi-Sankyo; grants from Italfarmaco; and grants from Alexion Pharmaceuticals. MP reports compensation from SANOFI-AVENTIS US LLC for other services; compensation from PFIZER CANADA for other services; compensation from iRhythm Technologies for other services; compensation from Daiichi Sankyo Europe GmbH for other services; and compensation from Bristol-Myers Squibb for other services. The other authors have nothing to disclose., (© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.)
- Published
- 2024
- Full Text
- View/download PDF